Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cinclus Pharma Holding AB ( (SE:CINPHA) ) just unveiled an update.
Cinclus Pharma reported net sales of TSEK 43,839 for the period January to September 2025, marking a significant increase from zero in the previous year. Despite this, the company faced a net loss of TSEK -122,788, highlighting ongoing financial challenges. The cash flow for the period was negative, with cash and cash equivalents totaling TSEK 540,220 at the end of the period. These financial results underscore the company’s continued investment in R&D, which constitutes 85% of its operating expenses, as it seeks to strengthen its position in the pharmaceutical market.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB operates in the pharmaceutical industry, focusing primarily on the development of treatments for gastroesophageal reflux disease (GERD). The company is engaged in research and development, with a significant portion of its operating expenses dedicated to R&D efforts.
Average Trading Volume: 65,889
Technical Sentiment Signal: Hold
Current Market Cap: SEK828.4M
See more insights into CINPHA stock on TipRanks’ Stock Analysis page.